Synaptogenix expecting data from its Phase 2 clinical trial
of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter
2022
NEW
YORK, Sept. 28, 2022 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the
"Company"), an emerging biopharmaceutical company developing
regenerative therapeutics for neurodegenerative disorders, today
commented on the positive Phase 3 trial results for Lecanemab
announced last night by Eisai and Biogen.
Dr. Daniel Alkon, President and
Chief Scientific Officer of Synaptogenix, stated, "We continue to
welcome the significant commitment that Biogen and Eisai are making
towards developing a new treatment option for Alzheimer's disease
(AD). Synaptogenix shares the same commitment to treat AD, although
the focus of Synaptogenix resources are toward the actual
restoration of function and disease reversal, versus a singular
focus on slowing the disease's rate of clinical decline. The
Synaptogenix lead compound Bryostatin-1, now in an extended
clinical trial, is believed to work on regeneration of brain wiring
(synaptic networks), in addition to a reduction of amyloid that is
targeted by the Biogen/Eisai compound. Regeneration of brain wiring
may result in actual improvement of patients' cognitive
performance, not just slowing of cognitive decline - as we reported
for exploratory analyses of previous Bryostatin trial results in
the Journal of Alzheimer's Disease a few months ago. We
believe that innovative, potentially restorative drug targets will
add to the potential therapeutic benefits that FDA-approved
medications must eventually offer to the millions of AD patients.
We are excited to present our Phase 2 data during the fourth
quarter of this year."
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies for
neurodegenerative diseases. Synaptogenix has conducted clinical and
preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated Bryostatin's regenerative mechanisms of action for the
rare disease, Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its
website: www.synaptogen.com .
Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 clinical trial of Bryostatin-1 and further
studies, and continued development of use of Bryostatin-1 for AD
and other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy, that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand its business, significant
government regulation of pharmaceuticals and the healthcare
industry, lack of product diversification, availability of the
Company's raw materials, existing or increased competition, stock
volatility and illiquidity, and the Company's failure to implement
its business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission. The Company does not
undertake to update these forward-looking statements.
Contact information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-welcomes-lecanemab-phase-3-trial-results-301635747.html
SOURCE Synaptogenix, Inc.